A Long-Term Study of Photodynamic Therapy with Verteporfin for Choroidal Neovascularization at the Edge of Chorioretinal Atrophy in Pathologic Myopia

Pece, Alfredo; Milani, Paolo; Isola, Vincenzo; Pierro, Luisa

doi:10.1159/000322362

Cited by 8 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some are also used to treat the Bowen's disease and basal cell carcinoma [40] . Moreover, for serious ocular diseases such as age-related macular degeneration and myopic choroidal neovascularization there is a clinically approved PS called Verteporfin in current use [108,109] . In 1993, Porfimer sodium (Photofrin) was the first PS approved for clinical used of PDT by the Canadian Health Agency for bladder cancer treatment.…”

Section: Clinical Applications Of Pdt; Combination With Other Therapimentioning

confidence: 99%

Photodynamic therapy in cancer treatment - an update review

Santos¹,

Almeida²,

Terra³

et al. 2019

JCMT

316

327

View full text Add to dashboard Cite

Cancer remains a worldwide health problem, being the disease with the highest impact on global health. Even with all the recent technological improvements, recurrence and metastasis still are the main cause of death. Since photodynamic therapy (PDT) does not compromise other treatment options and presents reduced long-term morbidity when compared with chemotherapy or radiotherapy, it appears as a promising alternative treatment for controlling malignant diseases. In this review, we set out to perform a broad up-date on PDT in cancer research and treatment, discussing how this approach has been applied and what it could add to breast cancer therapy. We covered topics going from the photochemical mechanisms involved, the different cell death mechanisms being triggered by a myriad of photosensitizers up to the more recent-on-going clinical trials.Metastatic lesions are usually multiple and resistant to conventional therapies, jeopardizing successful surgical resection, chemo and radiation treatment [4] .Light has been known to provide a therapeutic potential for several thousands of years. Over 3000 years ago, since the Ancient, Indian and Chinese civilizations it has been used for the treatment of various diseases [5] mainly in combination with reactive chemicals, for example to treat conditions like vitiligo, psoriasis and skin cancer [6] . After 1895 with the discovery of the phototherapy, which rendered Niels Ryberg Finsen the Nobel prize in Physiology/Medicine in 1903 in recognition of his work on the treatment of diseases, and in particular on the treatment of lupus vulgaris by means of concentrated light rays, many studies with the use of light and chemicals emerged [7] .Photodynamic therapy (PDT) is currently being used as an alternative treatment for the control of malignant diseases [8][9][10] . It is based in the uptake of a photosensitizer (PS) molecule which, upon being excited by light in a determined wavelength, reacts with oxygen and generates oxidant species (radicals, singlet oxygen, triplet species) in target tissues, leading to cell death [11,12] . PDT cytotoxic properties have been established to be due to the oxidation of a large range of biomolecules in cells, including nucleic acids, lipids, and proteins, leading to severe alteration in cell signaling cascades or in gene expression regulation [13,14] . Like all the newly proposed treatments, there is still place for improvements and lots of resources have been invested in this field recently. In this review, we set out to perform a broad up-date on PDT and it implication in cancer research and treatment. We have covered topics going from the photochemical mechanisms involved, the different cell death mechanisms being triggered by a myriad of photosensitizers up to the more recent reported preclinical studies and on-going clinical trials. PHOTOCHEMICAL PRINCIPLES AND COMPONENTS OF PDTAs previously stated, PDT involves the photosensitized oxidation of biomolecules which can be separated in two mechanisms. In Type I, light energy passes from exc...

show abstract

Section: Clinical Applications Of Pdt; Combination With Other Therapimentioning

confidence: 99%

Photodynamic therapy in cancer treatment - an update review

Santos¹,

Almeida²,

Terra³

et al. 2019

JCMT

316

327

View full text Add to dashboard Cite

show abstract

“…Visudyne® (Verteporfin, Novartis) is a benzoporphyrin derivative of verteporfin (Fig. 3f ) Verteporfin therapy is considered as a first-line therapy for serious ocular diseases; age-related macular degeneration and myopic choroidal neovascularization [ 56 , 57 ]. For the cancer treatment, Verteporfin is administrated by intravenously and activated by red-shifted and intensified laser absorption with 690 nm wavelength.…”

Section: Pss For Anticancer Pdtmentioning

confidence: 99%

Clinical development of photodynamic agents and therapeutic applications

2018

View full text Add to dashboard Cite

BackgroundPhotodynamic therapy (PDT) is photo-treatment of malignant or benign diseases using photosensitizing agents, light, and oxygen which generates cytotoxic reactive oxygens and induces tumour regressions. Several photodynamic treatments have been extensively studied and the photosensitizers (PS) are key to their biological efficacy, while laser and oxygen allow to appropriate and flexible delivery for treatment of diseases.IntroductionIn presence of oxygen and the specific light triggering, PS is activated from its ground state into an excited singlet state, generates reactive oxygen species (ROS) and induces apoptosis of cancer tissues. Those PS can be divided by its specific efficiency of ROS generation, absorption wavelength and chemical structure.Main bodyUp to dates, several PS were approved for clinical applications or under clinical trials. Photofrin® is the first clinically approved photosensitizer for the treatment of cancer. The second generation of PS, Porfimer sodium (Photofrin®), Temoporfin (Foscan®), Motexafin lutetium, Palladium bacteriopheophorbide, Purlytin®, Verteporfin (Visudyne®), Talaporfin (Laserphyrin®) are clinically approved or under-clinical trials. Now, third generation of PS, which can dramatically improve cancer-targeting efficiency by chemical modification, nano-delivery system or antibody conjugation, are extensively studied for clinical development.ConclusionHere, we discuss up-to-date information on FDA-approved photodynamic agents, the clinical benefits of these agents. However, PDT is still dearth for the treatment of diseases in specifically deep tissue cancer. Next generation PS will be addressed in the future for PDT. We also provide clinical unmet need for the design of new photosensitizers.

show abstract

“…К числу общих недостат-ков указанных методов лечения относят: нестабильные функциональные результаты и высокую частоту перси-стенции, а также рецидивы ХНВ [15,16].…”

unclassified